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Bloodborne viruses in Dublin’s opiate users 
A sustained effort has been made to bring methadone maintenance and needle exchange to 
Dublin’s drug using community since a report issued in 1992 showed that the cumulative AIDS 
incidence in injecting drug users in Ireland was exceeded only by Spain, Italy, and France among 
the then 12 member states of the European Community (1). The countries with the biggest drug 
related AIDS epidemics had been slower to adopt harm reduction as a strategy. In 1992, 150 of 
Dublin’s opiate users were receiving methadone. By May 1999 this had increased to 3750 (2) and 
the total now stands at 4312. An analysis of needle exchange provision showed that between 1990 
and 1997 inclusive there had been 6025 new attenders at needle exchange in Dublin, 2986 of 
them between 1995 and 1997 (3). 
Risk behaviour (needle sharing and not using condoms) in the 12 months before first attending 
needle exchange has become less common in these eight years (3). Another Dublin study showed 
that younger injectors (under 25 years of age) were more likely to have multiple sexual partners 
and to have shared injecting equipment. They were less likely to have had a HIV lest or to have 
been vaccinated against hepatitis B (4). 
The prevalence of HIV infection among attenders at needle exchange in Dublin in 1991 was 15% 
(5), compared with 1 % in a study carried out between 1992 and 1997 in a large treatment setting 
(6). The prevalence of hepatitis C in drug users in treatment also fell during the 1990s. It was 
84% in 1993 (7), and in another study declined from 65% in a pre-1994 cohort to 40% in a cohort 
who started injecting after the start of 1994 (8). Published data on the prevalence of hepatitis B in 
Dublin’s drug users is sparse, but one study found the prevalence of hepatitis B surface antigen to 
be 1% (6). 
Arrangements have been put in place for the routine surveillance of bloodborne viral infections in 
opiate users who attend for treatment in Dublin. Efforts arc also being redoubled to increase their 
vaccination rates against hepatitis B. Transmission of HIV has been controlled to a certain degree 
by the expansion of harm reduction services. Control of hepatitis C infection in injecting drug 
users will require new strategies. The percentage of opiate takers in Dublin who inject is 
 
higher than in other countries and cities where it has been examined, and the age at which people 
begin to inject is also younger (9). If injectors are at risk of acquiring hepatitis C infection very 
early in their injecting careers, it may be necessary to consider introducing methadone treatment 
for people who smoke heroin before they develop an injecting habit. A delicate balance has to be 
struck between limiting transmission of hepatitis C through early intervention with methadone 
and the risk of intervening before addiction has become established. A further complicating factor 
is that with the earlier age of onset of opiate addiction in Dublin, young injectors present for 
support from health services at an age when parental consent is still required before treatment is 
instituted. Such parental consent may be difficult to obtain in many cases. 
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